|
|
|
|
|
Market Research Report
Market Access, Pricing, and Reimbursement News in the Third Quarter of 2009
|
Market Access, Pricing, and Reimbursement News in the Third Quarter of 2009 published by Decision Resources, Inc. in October, 2009. This report consists of 40 Pages and the price starts from US $ 4600.
Abstract
Introduction:
The third quarter of 2009 saw a heated debate in the United States over
healthcare reform, the publication of a report on a European investigation of
the pharmaceutical industry, the election of new governments in Japan and
Germany, and new initiatives by governments in other countries to control
their national pharmaceutical spending. Faced with declining revenues and
increasing expenditures, healthcare payers in all markets are exerting
increasing pressure on the pharmaceutical industry to cut costs and deliver
genuine innovation.
Questions Answered in This Report:
- In the United States, the Democrats are committed to passing healthcare
reform legislation by the end of the year. What difficulties have lawmakers
encountered in drafting legislation? What are the recent trends in health
insurance coverage in the United States? What deal has the U.S. government
struck with the pharmaceutical industry?
- The French government is looking to cut $2 billion from the national
healthcare budget in 2010. How much does the government hope to save by
cutting prices, reducing the reimbursement rate of certain drugs, and
stimulating greater use of generics? What impact are new voluntary physician
contracts likely to have on the French pharmaceutical market?
- Spending on prescription drugs by the German statutory health insurance
system grew by 5.3% in 2008. How did spending and pricing trends compare for
generic and branded drugs? What changes would some health insurance funds like
the government to make to controls on pharmaceutical coverage? What new
restriction has the government introduced on coverage for certain cancers?
- The economic downturn is beginning to have an impact on the U.K.
healthcare system. What is the effect on pharmaceutical budgets? How have
recent price cuts and exchange rate movements altered parallel trade patterns
and contributed to shortages of certain drugs?
- The Japanese pricing and reimbursement environment faces the prospect of
significant changes in the coming years. How is the new government likely to
respond to industry proposals for a price maintenance system? How will
generics feature in future government healthcare policy? What are the
implications of a recently confirmed restriction on access to drugs not yet
approved in Japan?
Scope:
- Issues affecting the pharmaceutical industry in the United States:
healthcare reform; health insurance trends; drug benefit trends; managed care
executives' views on comparative effectiveness research; regulatory pathway
for biosimilars.
- Issues affecting the pharmaceutical industry in Europe: market trends;
generic drug use; proposed prescribing and reimbursement restrictions;
shifting patterns of parallel trade; impact of the economic downturn on the
pharmaceutical market; access to medicines.
- Issues affecting the pharmaceutical industry in Japan: prospects for the
introduction of a price maintenance system; government policy on generics;
reimbursement of drugs not yet approved in Japan.
Mentioned in This Report:
Companies and Organizations
- Agenzia Italiana del Farmaco (AIFA; Italian Medicines Agency)
- American Hospital Association
- Audiencia Nacional de Espana (National Court of Spain)
- Caisse Nationale d' Assurance Maladie (CNAM; National Health Insurance Fund)
- Catholic Health Association
- Center for Studying Health System Change (HSC)
- Centers for Disease Control and Prevention (CDC)
- Chuikyo (Central Social Insurance Medical Council)
- Congressional Budget Office (CBO)
- Federal Trade Commission (FTC)
- Federation of American Hospitals
- Federation of Pharmaceutical Manufacturers Associations of Japan (FPMAJ)
- Gemeinsamer Bundesausschuss der Arzte, Zahnarzte, Krankenhauser und
Krankenkassen (GBA; Joint Federal Committee of Physicians, Dentists,
Hospitals, and Health Insurance Funds)
- Haute Autorite de Sante (HAS; National Health Authority)
- Health Research & Educational Trust (HRET)
- Kaiser Commission on Medicaid and the Uninsured (KCMU)
- Kaiser Family Foundation (KFF)
- Pharmaceutical Research and Manufacturers of America (PhRMA)
- Pharmacy Benefit Management Institute (PBMI)
- Servicio de Inspeccion (Inspection Service)
- U.S. Census Bureau
- Wissenschaftliches Institut der Allgemeinen Ortskrankenkassen (WIdO;
Scientific Institute of the General Local Insurance Funds)
Table of Contents
- Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Overview
- United States
- Healthcare Reform
- An Increasingly Heated Debate
- Slow Progress of Healthcare Reform Legislation
- Government Deals with the Pharmaceutical Industry and Hospitals
- Health Insurance Trends
- U.S. Census Bureau Survey
- Centers for Disease Control and Prevention Survey
- Kaiser Family Foundation/Health Research & Educational Trust Employer
Survey
- Kaiser Commission on Medicaid and the Uninsured Survey
- Drug Benefit Trends
- Comparative Effectiveness Research
- Regulatory Pathway for Biosimilars
- European Union
- Publication of the Final Report of the Pharmaceutical Sectoral Inquiry
- France
- New Cost-Containment Measures Proposed for 2010
- Continued Steady Growth in the Generics Market
- Germany
- Market Trends
- Pressure for Reform from Health Insurance Funds
- Expansion of the Second Opinion Process
- New Government' s Deliberations on Healthcare Policy
- Italy
- Creation of a New Working Group on Access to Medicines
- Italian Medicines Agency' s New Focus on Pharmaceutical Strategy and
Economic Policy
- Spain
- Double Legal Setback for the Pharmaceutical Industry
- United Kingdom
- Economic Slowdown Exerts Pressure on Prescribing Budgets
- Supply Shortages Resulting from Parallel Exports
- Likely Delay to the Introduction of Generics Substitution
- Review of NICE' s Infl uence on Pharmaceutical Innovation
- Japan
- Prospective Trial Introduction of a Price Maintenance System
- New Government Likely to Stimulate the Generics Market
- Barrier to Reimbursement of Drugs Not Yet Approved in Japan
- Outlook and Implications for the Pharmaceutical Industry
Tables
- 1. Key Proposals for U.S. Healthcare Reform
Figures
- 1. Health Insurance Coverage of the Total U.S. Population, 1999-2008
- 2. Health Insurance Coverage of the Nonelderly U.S. Population, 1999-2008
- 3. Health Insurance Coverage of the Senior U.S. Population, 1999-2008
- 4. Percentage of U.S. Employers Sponsoring Employee Health Benefits,
1999-2009
- 5. U.S. Employers That Sponsor Employee Health Benefits: Likelihood of
Implementing Various Cost-Containment Measures in the Next Year
- 6. Percentage of U.S. Covered Workers in Formulary Designs of Various
Structures, 2000-2009
- 7. Average Copayments in the United States by Formulary Tier, 2000-2009
- 8. Average Coinsurance Rates in the United States by Formulary Tier,
2000-2009
- 9. U.S. Employers' Use of Common Utilization Management Tools, 2007-2009
- 10. U.S. Managed Care Executives' Priorities for Comparative Effectiveness
Research
- 11. Generics' Share of the Japanese Pharmaceutical Market, Fiscal Years
2006-2008
|
 |
